News: Umeå, 13 May 2022. Lipum AB (publ) has started a collaboration with Pelago Bioscience AB to strengthen the bioanalytical development for pre-clinical and clinical studies.
Pelago Bioscience AB is a fast-growing Swedish company, based in Solna, with bioanalytical expertise and services for drug discovery and development. Pelago has capacity to provide LC-MS based protein quantification assays as a service for pharmacodynamic, pharmacokinetic or biomarker monitoring during drug development. Initially, the collaboration with Lipum will focus on drug target monitoring during clinical studies of the lead candidate SOL-116.
“Sweden is at the forefront of bioanalytical chemistry and therefore I am very pleased that we have started cooperation with Pelago in Solna. This means a strengthening of our development work and the opportunity for more valuable results from clinical studies on our lead candidate SOL-116”, says Einar Pontén, CEO.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 5783495
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.